Reaction
Lymphoma Transformation reporting signals
As of the last recalculation, Lymphoma Transformation appears in 356 FAERS reports alongside 16 co-occurring drug terms. The strongest observed disproportionality signal is POLATUZUMAB VEDOTIN (PRR 262.3).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Polatuzumab Vedotin | 39 | 262.3 | 263.3 |
| Bendamustine Hydrochloride | 36 | 195.4 | 196.0 |
| Bendamustine Hcl | 38 | 160.3 | 160.7 |
| Obinutuzumab | 40 | 160.0 | 160.4 |
| Rituximab | 212 | 143.5 | 143.6 |
| Doxorubicin | 91 | 79.9 | 79.9 |
| Ifosfamide | 22 | 63.7 | 63.8 |
| Vincristine Sulfate | 28 | 60.5 | 60.6 |
| Doxorubicin Hydrochloride | 30 | 58.6 | 58.6 |
| Bleomycin Sulfate | 8 | 46.3 | 46.3 |
| Durvalumab | 15 | 45.0 | 45.0 |
| Cyclophosphamide Injection, Solution | 94 | 41.8 | 41.8 |
| Cyclophosphamide | 94 | 41.8 | 41.8 |
| Cyclophosphamide For Injection | 94 | 41.8 | 41.8 |
| Etoposide | 32 | 27.9 | 27.9 |
| Atezolizumab | 16 | 25.2 | 25.2 |